Antiplatelet and antithrombotic effect of F 16618, a new thrombin proteinase-activated receptor-1 (PAR1) antagonist

British Journal of Pharmacology

Volumn 165, Issue 6, 2012, Pages 1827-1835

  Dumas, M ^a,b   Nadal Wollbold, F ^c   Gaussem, P ^a,b,d   Perez, M ^c   Mirault, T ^a,b,d   Letienne R ^c   Bourbon, T ^c   Grelac, F ^a,b   Le Grand, B ^c   Bachelot Loza, C ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

aggregation; antiplatelet agent; arterial thrombosis; PAR1 antagonist; platelets

Indexed keywords

2 [5 OXO 5 (4 PYRIDIN 2 YL PIPERAZIN 1 YL)PENTA1,3 DIENYL]BENZONITRILE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; COLLAGEN; NEW DRUG; PADGEM PROTEIN; PROTEINASE ACTIVATED RECEPTOR 4; THROMBIN; THROMBIN RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD ANALYSIS; BLOOD CLOT LYSIS; CAROTID ARTERY THROMBOSIS; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG POTENCY; EX VIVO STUDY; EXPERIMENTAL GUINEA PIG; HEMOSTASIS; HUMAN; HUMAN CELL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE; THROMBOCYTE AGGREGATION INHIBITION;

ANIMALS; CAROTID ARTERY THROMBOSIS; COLLAGEN; FIBRINOLYTIC AGENTS; GUINEA PIGS; HEMOSTASIS; HUMANS; MALE; OLIGOPEPTIDES; PIPERAZINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PYRIDINES; RECEPTOR, PAR-1; THROMBIN;

EID: 84857465754     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01668.x     Document Type: Article

References (37)

1. Ahn HS, Foster C, Boykow G, Stamford A, Manna M, Graziano M, (2000). Inhibition of cellular action of thrombin by N3-cyclopropyl-7-[[4-(1- methylethyl)phenyl]methyl]-7H-pyrrolo[3, 2-f]quinazoline-1,3-diamine (SCH 79797), a nonpeptide thrombin receptor antagonist. Biochem Pharmacol 60: 1425-1434.
2. Alexander SPH, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th Edition. Br J Pharmacol 164 (Suppl. 1): S1-S324.
3. Andersen H, Greenberg DL, Fujikawa K, Xu W, Chung DW, Davie EW, (1999). Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity. Proc Natl Acad Sci USA 96: 11189-11193.
4. Andrade-Gordon P, Derian CK, Maryanoff BE, Zhang HC, Addo MF, Cheung W, et al,. (2001). Administration of a potent antagonist of protease-activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in rats. J Pharmacol Exp Ther 298: 34-42.
5. Bernatowicz MS, Klimas CE, Hartl KS, Peluso M, Allegretto NJ, Seiler SM, (1996). Development of potent thrombin receptor antagonist peptides. J Med Chem 39: 4879-4887.
6. Bocquet A, Letienne R, Sablayrolles S, De Vries L, Perez M, Le Grand B, (2009). Effects of a new PAR1 antagonist, F 16618, on smooth muscle cell contraction. Eur J Pharmacol 611: 60-63.
7. Chackalamannil S, Wang Y, Greenlee WJ, Hu Z, Xia Y, Ahn HS, (2008). Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem 51: 3061-3064.
8. Chieng-Yane P, Bocquet A, Letienne R, Bourbon T, Sablayrolles S, Perez M, et al,. (2011). Protease activated Receptor-1 antagonist, F 16618 reduces arterial restenosis by down-regulation of TNF{alpha} and MMP7 expression, and migration and proliferation of vascular smooth muscle cells. J Pharmacol Exp Ther 336: 643-651.
9. Chung AW, Jurasz P, Hollenberg MD, Radomski MW, (2002). Mechanisms of action of proteinase-activated receptor agonists on human platelets. Br J Pharmacol 135: 1123-1132.
10. Coughlin SR, (2005). Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 3: 1800-1814.
11. Covic L, Gresser AL, Kuliopulos A, (2000). Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets. Biochemistry 39: 5458-5467.
12. Damiano BP, Derian CK, Maryanoff BE, Zhang HC, Gordon PA, (2003). RWJ-58259: a selective antagonist of protease activated receptor-1. Cardiovasc Drug Rev 21: 313-326.
13. Derian CK, Damiano BP, Addo MF, Darrow AL, D'Andrea MR, Nedelman M, et al,. (2003). Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. J Pharmacol Exp Ther 304: 855-861.
14. Gross PL, Weitz JI, (2009). New antithrombotic drugs. Clin Pharmacol Ther 86: 139-146.
15. Hirano K, Kanaide H, (2003). Role of protease-activated receptors in the vascular system. J Atheroscler Thromb 10: 211-225.
16. Jennings LK, (2009). Role of platelets in atherothrombosis. Am J Cardiol 103: 4A-10A.
17. Kahn ML, Zheng YW, Huang W, Bigornia V, Zeng D, Moff S, et al,. (1998). A dual thrombin receptor system for platelet activation. Nature 394: 690-694.
18. Kato Y, Kita Y, Nishio M, Hirasawa Y, Ito K, Yamanaka T, et al,. (1999). In vitro antiplatelet profile of FR171113, a novel non-peptide thrombin receptor antagonist. Eur J Pharmacol 384: 197-202.
19. Kato Y, Kita Y, Hirasawa-Taniyama Y, Nishio M, Mihara K, Ito K, et al,. (2003). Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig. Eur J Pharmacol 473: 163-169.
20. Kogushi M, Matsuoka T, Kawata T, Kuramochi H, Kawaguchi S, Murakami K, et al,. (2011). The novel and orally active thrombin receptor antagonist E5555 (Atopaxar) inhibits arterial thrombosis without affecting bleeding time in guinea pigs. Eur J Pharmacol 657: 131-137.
21. Letienne R, Leparq-Panissie A, Calmettes Y, Nadal-Wollbold F, Perez M, Le Grand B, (2010). Antithrombotic activity of F 16618, a new PAR1 antagonist evaluated in extracorporeal arterio-venous shunt in the rat. Biochem Pharmacol 79: 1616-1621.
22. Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, et al,. (2009). Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 119: 237-242.
23. Morrow DA, Scirica BM, Fox KA, Berman G, Strony J, Veltri E, et al,. (2009). Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. Am Heart J 158: 335-341.
24. Oestreich J, (2009). SCH-530348, a thrombin receptor (PAR-1) antagonist for the prevention and treatment of atherothrombosis. Curr Opin Investig Drugs 10: 988-996.
25. Perez M, Lamothe M, Maraval C, Mirabel E, Loubat C, Planty B, et al,. (2009). Discovery of novel protease activated receptors 1 antagonists with potent antithrombotic activity in vivo. J Med Chem 52: 5826-5836.
26. Ramachandran R, Hollenberg MD, (2008). Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more. Br J Pharmacol 153 (Suppl. 1): S263-S282.
27. Serebruany VL, Kogushi M, Dastros-Pitei D, Flather M, Bhatt DL, (2009). The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease. Thromb Haemost 102: 111-119.
28. Shapiro MJ, Weiss EJ, Faruqi TR, Coughlin SR, (2000). Protease-activated receptors 1 and 4 are shut off with distinct kinetics after activation by thrombin. J Biol Chem 275: 25216-25221.
29. Siller-Matula JM, Gouya G, Wolzt M, Jilma B, (2009). Cross validation of the Multiple Electrode Aggregometry. A prospective trial in healthy volunteers. Thromb Haemost 102: 397-403.
30. Smyth SS, Woulfe DS, Weitz JI, Gachet C, Conley PB, Goodman SG, et al,. (2009). G-protein-coupled receptors as signaling targets for antiplatelet therapy. Arterioscler Thromb Vasc Biol 29: 449-457.
31. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Jukema JW, Huisman MV, (2007). Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J 154: 221-231.
32. Vandendries ER, Hamilton JR, Coughlin SR, Furie B, Furie BC, (2007). Par4 is required for platelet thrombus propagation but not fibrin generation in a mouse model of thrombosis. Proc Natl Acad Sci USA 104: 288-292.
33. Vassallo RR, Kieber-Emmons T, Cichowski K, Brass LF, (1992). Structure-function relationships in the activation of platelet thrombin receptors by receptor-derived peptides. J Biol Chem 267: 6081-6085.
34. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al,. (2009). Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361: 1045-1057.
35. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al,. (2007). Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357: 2001-2015.
36. Wu CC, Teng CM, (2006). Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation. Eur J Pharmacol 546: 142-147.
37. Wu CC, Wu SY, Liao CY, Teng CM, Wu YC, Kuo SC, (2010). The roles and mechanisms of PAR4 and P2Y12/phosphatidylinositol 3-kinase pathway in maintaining thrombin-induced platelet aggregation. Br J Pharmacol 161: 643-658.